What is Hexarelin?

What is Hexarelin, exactly?

Hexarelin is a synthetic peptide — a chain of six amino acids (His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys) — designed to stimulate the body's own release of growth hormone. Its international name is examorelin.[2]

It belongs to the growth hormone-releasing peptide (GHRP) family — the same class as GHRP-2 and GHRP-6 — developed in the Bowers/Deghenghi/Ghigo research lineage. Like its relatives it's a growth hormone secretagogue: it prompts the pituitary to secrete GH rather than being GH itself.[2]

What makes hexarelin notable within that family is a second target. Beyond the ghrelin receptor every GHRP uses, hexarelin also binds CD36 — a scavenger receptor on heart-muscle cells — which gives it direct cardiovascular activity largely independent of growth hormone.[3] That dual identity, plus its tendency to desensitize with repeated use, is the whole story of why hexarelin is studied and discussed.

Is Hexarelin a peptide?

Yes — Hexarelin is a peptide. Specifically it's a hexapeptide: a chain of six amino acids (His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys), which is where the "hexa" in its name comes from.[2]

Several of its residues are modified or D-amino acids — mirror-image building blocks that enzymes break down more slowly — which makes this synthetic peptide more stable than a fully natural sequence.

What does Hexarelin do?

Hexarelin does two distinct things, which is what sets it apart. The actions described in the research are:

• Releases growth hormone. In humans, hexarelin produces a strong GH pulse — larger than GH-releasing hormone alone in head-to-head testing.[2]
• Acts on the heart via CD36. Independently of GH, hexarelin binds CD36 on cardiac cells and has been studied for direct cardioprotective effects — a feature emphasised for hexarelin more than other GHRPs.[3]
• Nudges other hormones. Like the GHRP class, it transiently raises cortisol and prolactin (and ACTH), though its prolactin effect is modest.[2]
• Desensitizes over time. Repeated exposure in controlled studies progressively reduced the GH response.[4]

The honest framing: these are short-term endocrine and preclinical findings. They establish that hexarelin reliably releases GH and engages CD36 — not that self-administering it delivers any proven muscle, recovery, anti-aging or heart-disease outcome. Those popular framings are research-stage extrapolations.

How does Hexarelin work?

Hexarelin works through two receptors, which is the key to understanding it.

Hexarelin's ghrelin-receptor (GHS-R1a) pathway

The GH side runs through the growth hormone secretagogue receptor (GHS-R1a) — the receptor cloned in 1996 and later identified as ghrelin's target.[1] Activating it tells the pituitary's somatotroph cells to release stored GH, through a pathway separate from GH-releasing hormone (and one that also synergizes with it). This is the mechanism hexarelin shares with the whole GHRP family.

Hexarelin vs GHRP-2 and GHRP-6 — the CD36 difference

Where hexarelin diverges from GHRP-2 and GHRP-6 is the CD36 receptor on heart cells, which mediates direct cardiovascular effects independent of growth hormone.[3] Controlled repeated-exposure studies also reported a partially reversible attenuation of the GH response.[4] See the GHRP-2 & GHRP-6 guide for the rest of the family.

Hexarelin peptide benefits

The Hexarelin peptide benefits discussed in research follow from its two actions — the GH pulse and the CD36 cardiac effect:

• Growth-hormone release. A strong, reliable GH pulse in human testing, the basis of the recovery/body-composition interest.[2]
• Cardiac interest. Direct CD36-mediated cardioprotective effects in preclinical models — the feature that distinguishes hexarelin.[3]

The honest qualifier — repeated deliberately — is that the evidenced findings are the acute GH pulse in short human studies and cardiac effects in preclinical models; the muscle, fat-loss, anti-aging and heart-health claims are extrapolations, not outcomes proven for hexarelin. And because of desensitization, even the GH benefit fades on continuous use.[4] These are research findings, not promised results, and hexarelin is not an approved treatment for any of them.

Hexarelin side effects

In the controlled studies, hexarelin was generally well tolerated short-term, but it carries the GHRP class effects plus its own quirk. The documented and reported effects are:

• Transient cortisol & prolactin rise. A class effect of the GHRPs, documented for hexarelin in human work (its prolactin effect is modest).[2]
• Desensitization. Controlled studies found a progressive, partially reversible decline in GH response with repeated exposure.[4]
• Community-reported. Injection-site reactions, water retention and tingling — anecdotal, not trial endpoints.

The key honesty point is the same as for its GHRP siblings: there's no long-term human safety data for repeated hexarelin self-administration. The literature is short-term endocrine studies and preclinical cardiac work, not safety trials.

Is Hexarelin safe and FDA approved?

No — Hexarelin is not FDA-approved and has no marketing approval anywhere; it's handled as a research chemical. For athletes, hexarelin is explicitly named on the WADA Prohibited List — listed as "examorelin (hexarelin)" under class S2 (GH-releasing peptides), banned at all times.

How to choose Hexarelin

For a research peptide with no GMP supply chain, material quality is the dominant variable — endotoxin and impurities, not the molecule, are the realistic risks. A batch-specific Certificate of Analysis (UPLC purity, identity, endotoxin) does more for safety than any community convention; the absence of a recent, lot-matched CoA is itself a risk signal.

Common questions

Related research peptide guides

GHRP-2 GHRP-6

References

1. Howard AD, Feighner SD, Cully DF, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science, 1996;273(5277):974–977. PMID 8688086. (GHS-R cloning — the ghrelin/GHRP receptor.)
2. Arvat E, di Vito L, Maccagno B, et al. Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man. Peptides, 1997;18(6):885–891. PMID 9285939. (Hexarelin strong GH response; modest prolactin; cortisol/ACTH.)
3. Bodart V, Febbraio M, Demers A, et al. CD36 mediates the cardiovascular action of growth hormone-releasing peptides in the heart. Circ Res, 2002;90(8):844–849. PMID 11988484. (Hexarelin's CD36 cardiac mechanism.)
4. Rahim A, O'Neill PA, Shalet SM. Growth hormone status during long-term hexarelin therapy. J Clin Endocrinol Metab, 1998;83(5):1644–1649. PMID 9589671. (Desensitization over 16 weeks — partial & reversible.)

Hexarelin (examorelin) is a synthetic hexapeptide GH secretagogue acting at the ghrelin receptor (GHS-R1a) [1], with reported endocrine effects [2], CD36 activity [3], and partially reversible desensitization in a controlled repeated-exposure study [4]. It is not FDA-approved and is WADA-prohibited as "examorelin (hexarelin)" (class S2 — verified against the 2026 Prohibited List). Muscle, anti-aging and heart claims remain research-stage extrapolations; community claims are vendor-derived and unverified. Not medical advice.

For research use only. Not for human consumption. This page summarises published research for educational purposes. It is not medical advice and is not intended to diagnose, treat, cure, or prevent any disease.